Delix Therapeutics

Drug Discovery · Bedford, MA · Founded 2019 · Privately Held (backing)

Developer of neuroscience therapeutics designed to address mental health and central nervous system conditions. Delix Therapeutics is based in Bedford, MA and was founded in 2019. It was valued at $156 million at a grant in Jun 2024, the last priced event on record. It has raised $109 million across 1 recorded round; the latest was a $70 million Series A in Sep 2021.

PMV mark · valuation
$156.2M
Oct 2026
Priced at
a grant
Jun 2024
Total raised
$108.5M
Last round
Early Stage VC (Series A)
Sep 2021
What is Delix Therapeutics worth?
$156.2MPrivateMarketView mark · Oct 2026

Valued at $156.2M at a grant, Jun 2024. Nothing has traded since.

Free account
More of Delix Therapeutics with a free account
  • ·The complete investor list: 40 names
  • ·Watch Delix Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Delix Therapeutics funding history

1 rounds
DateRoundRaisedPost-money
Sep 2021Early Stage VC (Series A)$70.0M▮
Unlock post-money valuations

Membership and data by Private Market View

Delix Therapeutics valuation

Delix Therapeutics was valued at $156 million at a grant in Jun 2024. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Delix Therapeutics raised?

Delix Therapeutics has raised $109 million in total; 1 of its rounds is on record. The largest on record was a $70 million Series A in Sep 2021.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Gordian Biotechnology ($170 million), Claris Bio ($163 million) and Sparrow Pharmaceuticals ($139 million).

How Delix Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Delix Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Delix Therapeutics

What is Delix Therapeutics worth?
Delix Therapeutics is valued at $156.2M as of Oct 2026. Valued at $156.2M at a grant, Jun 2024. Nothing has traded since.
How much has Delix Therapeutics raised?
Delix Therapeutics has raised $108.5M in total funding across 1 recorded rounds.
When did Delix Therapeutics last raise?
Delix Therapeutics last raised in Sep 2021 (Early Stage VC (Series A)), raising $70.0M.